Piracetam and Piracetam-Like Drugs

@article{Malykh2012PiracetamAP,
  title={Piracetam and Piracetam-Like Drugs},
  author={Andrei G. Malykh and M. Reza Sadaie},
  journal={Drugs},
  year={2012},
  volume={70},
  pages={287-312}
}
There is an increasing interest in nootropic drugs for the treatment of CNS disorders. Since the last meta-analysis of the clinical efficacy of piracetam, more information has accumulated. The primary objective of this systematic survey is to evaluate the clinical outcomes as well as the scientific literature relating to the pharmacology, pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicology and adverse effects of marketed and investigational drugs. The major focus of the… Expand
Drug therapies for tardive dyskinesia: part 2.
  • R. Howland
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2011
TLDR
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs, and a number of drugs appear to have some benefit for its treatment. Expand
Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice
TLDR
The study showed that R-PhP possesses neuroprotective and anti-inflammatory effects, demonstrating the potential of DAT inhibitors as effective therapeutics. Expand
Stereochemistry of phenylpiracetam and its methyl derivative: improvement of the pharmacological profile
Since the discovery of piracetam its structural analogs based on the pyrrolidin-2-one pharmacophore have aroused great interest as a source of effective pharmacological central nervous systemExpand
(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats
TLDR
The results strongly suggest that (S)-oxiracetam alone could be a nootropic drug for the treatment of cognitive impairments caused by cerebral hypoperfusion. Expand
Drug therapies for cognitive impairment and dementia.
  • R. Howland
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2010
TLDR
Clinical trials in a diverse group of patients with age-related dementia or cognitive impairment demonstrated a significant benefit, but the methodology of these studies is poor, and long-term effects are unknown. Expand
Investigation into stereoselective pharmacological activity of phenotropil.
TLDR
The antidepressant and increased locomotor activity relies on both R- and S-phenotropils, but the memory-improving activity is only characteristic of R-phenotropic, which may be important for the clinical use of optically pure isomers of phenotropil. Expand
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
TLDR
This review provides up-to-date information on the selective targeting of σ1 receptors, including their history, function, reported crystal structures, and roles in neurological diseases, as well as a useful collation of new chemical entities as ρ1 selective orthosteric ligands or allosteric modulators. Expand
Pharmacokinetics of oxiracetam and its degraded substance (HOPAA) after oral and intravenous administration in rats
Abstract The pharmacokinetics of oxiracetam and its degraded substance (4-hydroxy-2-oxo-1-pyrrolidine acetic acid, HOPAA) after oral and intravenous administration in rats were studied using anExpand
Effects of novel hexahydropyrimidine derivatives as potential ligands of M1 muscarinic acetylcholine receptor on cognitive function, hypoxia-induced lethality, and oxidative stress in rodents
TLDR
The results indicate that hexahydropyrimidine derivatives have a beneficial effect on the memory, learning processes, and orientation and locomotor activities of rats in an unfamiliar environment and exhibit antihypoxic and antioxidant activities under hypoxia in mice. Expand
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
TLDR
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 18 categories according to their mechanism(s) of action. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 158 REFERENCES
A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke
TLDR
The evidence supporting a protective effect of piracetam and its derivatives in animal models of stroke is described, but concerns are raised about the amount of available data, the quality of the studies and publication bias. Expand
Seletracetam (UCB 44212)
TLDR
Results suggest that seletracetam represents a promising new antiepileptic drug candidate, one that demonstrates a potent, broad spectrum of seizure protection and a high CNS tolerability in animal models, with initial clinical findings suggestive of straightforward pharmacokinetics and good tolerability. Expand
Brivaracetam: a new drug in development for epilepsy and neuropathic pain
TLDR
Brivaracetam represents a new mechanism of action being a ligand of synaptic vesicle protein 2A and is undergoing Phase III evaluation after a successful Phase II programme in which was effective as an adjunctive treatment in partial-onset epilepsy. Expand
Piracetam: physiological disposition and mechanism of action.
TLDR
Experimental and clinical data on piracetam's absorption, distribution, and excretion are summarized, and biochemical data available that bear on its mechanism of action are described. Expand
Brivaracetam: a rational drug discovery success story
TLDR
Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target and is efficacious and well tolerated in the treatment of partial onset seizures. Expand
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
TLDR
Brivaracetam had a favourable pharmacokinetic profile in this population, characterized by rapid absorption, volume of distribution limited to total body water, apparent single-compartment elimination and dose proportionality. Expand
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
TLDR
Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose and was found to have desirable pharmacokinetic properties. Expand
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
TLDR
The detection of mild cognitive disorders is extremely important from the practical point of view, because therapeutic measures can have the greatest efficacy at this stage of cerebral insufficiency and the chances of obtaining compensation once dementia has developed are significantly restricted. Expand
The safety of levetiracetam
TLDR
The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. Expand
Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
TLDR
Reasons for the problems encountered by nootropics, compounds therapeutically available and those in development, their structure activity relationships and mechanisms of action are discussed and the class is examined in more detail. Expand
...
1
2
3
4
5
...